All In Biotech

Drug Trial Radar · NCT03058289

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers

Last checked: Nov 19, 2026Latest source record: Feb 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

111

Actual

Start

Feb 9, 2017

Primary completion

Feb 22, 2023

Study completion Feb 22, 2023

Sponsor

Lead sponsor
Intensity Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC; Bristol-Myers Squibb
First posted
Feb 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the skin (breast, squamous cell, head and neck) and tumors within the body such (pancreatic, colon, liver, lung, etc.). Sponsor also tested INT230-6 in combination with anti-PD-1 and anti-CTLA-4 antibodies.

Conditions

  • Breast Cancer
  • Head and Neck Cancer
  • Squamous Cell Carcinoma
  • Lymphoma
  • Pancreatic Cancer
  • Liver Cancer
  • Colon Cancer
  • Lung Cancer
  • Bile Duct Cancer
  • Chordoma of Sacrum
  • Sarcoma

Interventions

  • INT230-6Drug

    INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated. The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.

  • anti-PD-1 antibodyBiological

    The anti-PD-1 antibody will be added concomitantly with INT230-6 as noted in cohort DEC and DEC2

  • anti-CTLA-4 antibodyBiological

    The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate and Severity of Treatment-emergent Adverse Events ≥ Grade 3 Attributed to Study Drug Using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5)Time frame: Up to 5 years

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • USC Norris

    Los Angeles, California

  • USC HOAG

    Newport Beach, California

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • UMASS Memorial Medical Center

    Worcester, Massachusetts

  • Columbia University Medical Center

    New York, New York

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Center for Oncology and Blood Disorders

    Houston, Texas

  • Princess Margaret Cancer Center - University Health Network

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.